Kantify

Are you interested to better understand how Artificial Intelligence can help with repurposing of existing or old drugs for untreated diseases? Then you should join us next week to the live webinar on Drug Repurposing and Artificial Intelligence (AI) on Wednesday, October 30th, 2024 at 16:00 CEST / 11:00 EST (USA), organized by Global Market Access Solutions. This webinar will feature speakers who will provide insights into the role of AI in drug repurposing and its potential to address diseases with high unmet needs: David Fajgenbaum, MD, MBA, MSc, Associate Professor of Medicine at the University of Pennsylvania, President & Co-Founder of Every Cure , and bestselling author of Chasing My Cure. Nik Subramanian, Co-founder and Chief Technology Officer at Kantify, presenting recent breakthroughs made by Kantify’s AI platform, Sapian, in target discovery and drug repurposing. Cillian Copeland , Health Economist at Global Market Access Solutions Global Market Access Solutions, who will moderate the session, bringing expertise in the pricing and access of repurposed medicines. To attend this free webinar, please register via the link in comment. Looking forward to it! We look forward to your participation in this informative event. #DrugRepurposing #ArtificialIntelligence #Healthcare #Biotechnology #Webinar #Pharmaceuticals #EveryCure #Kantify #GMAS

What if Viagra had a hidden life? What if this secret life could be uncovered by AI? What if we could do the same for any small molecule? These are the questions that we tackle in our inaugural publication 𝘉𝘦𝘩𝘪𝘯𝘥 𝘵𝘩𝘦 𝘗𝘪𝘭𝘭. In 𝘉𝘦𝘩𝘪𝘯𝘥 𝘵𝘩𝘦 𝘗𝘪𝘭𝘭, you will discover how we have used our AI platform Sapian to predict the unknown biological targets of 78 000 drugs, including Sildenafil / Viagra. The result? No less than.... 2 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 interacted predictions between known molecules and the entire human proteome. By revealing previously unknown biological targets, Sapian's findings open the door to potential new therapeutic applications for existing or novel drugs, beyond their current uses. This could lead to breakthroughs in treating conditions that were previously overlooked, or uncover safety considerations that could further refine how we prescribe medications. What sets Sapian apart is its unparalleled ability to map interactions across the entire human proteome, analyzing complex multi-target profiles for any small molecule. ➡️ Watch this short video conversation between our CEO Ségolène and our COO Nicolas to understand more ➡️Check our inaugural publication to discover our findings on Sildenafil / Viagra https://lnkd.in/eU-66Upq ➡️ Contact us to uncover the secret life of your small molecule 💊

AI is transforming drug discovery, cutting years off development and accelerating the journey to market. Companies like Kantify are at the forefront, using their cutting-edge AI platform, Sapian, to identify promising drug candidates and design targeted protein degraders with unprecedented speed and accuracy. Their innovations are a game-changer, especially for rare diseases and complex conditions. How is your organization leveraging AI to stay ahead in drug discovery? #AI #DrugDiscovery #PharmaInnovation #Kantify

Join us at Science For Health! In the morning plenary, we will share how we use our AI technology Sapian for faster small molecule discovery for diseases which need it the most. #WeCare

Do you know that Kantify is the co-coordinator of the DREAMS consortium who has joined forces to identify promising drugs for 5 neuromuscular disorders? This project is extremely ambitious and is made possible by the unique combination of cutting edge technologies such as AI and induced Pluripotent Stem Cells. Our CEO Ségolène Martin explains below Kantify's and AI's contribution to the project ➡️

[News] AI unveils targets of drugs, starting with Viagra 📣 We are proud to announce today that our AI technology, Sapian, has been leveraged to predict the hidden side of known drugs. As part of an effort to accelerate the repurposing of existing drugs for new indications, Kantify has constituted a unique “Atlas” of how known drugs and molecules interact with all known human proteins. This AI-powered Atlas consists of no less than 78 000 drugs (natural compounds, investigational drugs, and approved drugs) and... 1.4 billion predictions of potential off-targets. In a first White Paper released today, we unveil the Sapian Atlas predictions for a very well known drug, Sildenafil (Viagra). This White Paper authored by Nicolas Maignan, Kantify's COO, presents our novel AI methodology and lists 245 predicted targets for Sildenafil. With this new Atlas, we wish to contribute to a better understanding of the numerous off-targets of drugs, even the ones we (think we) know best, such as Viagra. Find in first comment the link to the full inaugural White Paper and the link to the article published today in the front page of leading economics newspaper L'Echo ! Many thanks to Olivier Gosset 🖊️

[Announcement] We have known for a while now that it was high time to rename our AI platform for drug discovery. We unveil this new name today! "Sapian" is the new name of our Artificial Intelligence platform for drug discovery. The name "Sapian" is derived from "Sapiens," reflecting the platform's emphasis on intelligence and advanced predictive capabilities. "Sapiens," from the Latin "sapere," means "to be wise" or "to know," and is famously associated with "Homo sapiens," the species name for humans, signifying our unique intellectual abilities. By naming our AI platform Sapian, we want to underscore how we combine human-like wisdom and advanced artificial intelligence to revolutionize drug discovery and make treatments available for patients, faster.

On July 22, we celebrate the Fragile X Day with the FRAXA Research Foundation and many other communities worldwide. Fragile X Syndrome (FXS) is the most common inherited single gene cause of autism. At Kantify, we're using Artificial Intelligence to develop innovative treatments for Fragile X. Mathijs van der Lei of University of Antwerp (photo) recently presented at the Gordon Research Conferences how we are jointly using a new assay and AI to measure subtle changes in the behavior of FXS mouse models, making drug testing more efficient. We're testing multiple drugs, targeting different pathways in FXS. We've established an innovative drug screening protocol by combining the multi-electrode array (MEA) for neuronal activity and the live mouse tracker (LMT) for behavior analysis. Preliminary data show alterations in the spontaneous firing and behavior of Fmr1 KO compared to wild-type, offering powerful insights into drug effectiveness. Stay tuned to find out more about our next discoveries! #WorldFragileXDay #FragileX #Research #AI #Biotech #Cure #FRAXA #ResearchUpdates Frank Kooy Caio Hudson Queiroz de Souza Mathijs van der Lei Michael Tranfaglia Nicolas Maignan Nik Subramanian

Nice to see the work of Kantify mentioned in this new article from the Belgian Pharma association pharma.be, where the authors Karen Crabbé and Michèle Melhem explain the potential of Artificial Intelligence for patient-centered innovation in the biopharma sector. in French ➡️ https://lnkd.in/eHyRDGaq in Dutch ➡️ https://lnkd.in/eTBgqXnD

July is #SarcomaAwarenessMonth. Sarcoma is a rare and complex type of cancer that originates in the bones and soft tissues, including muscles, fat, blood vessels, and connective tissues. Due to its rarity, diverse manifestations and often subtle symptoms, sarcoma can be challenging to diagnose. It is still very difficult to treat sarcoma effectively. At Kantify we are working to accelerate the discovery of drugs for sarcomas thanks to new AI approaches. As we already shared on this page, we have very promising results. We will remain committed to make a difference for patients! #raredisease #sarcomaawarenessmonth #AI